Adagene's SAFEbody technology platform for generating masked monoclonal antibodies for ADC or other innovative biotherapeutic development against Exelixis-nominated oncology targets

SMARTag · Catalent

Catalent's SMARTag site-specific bioconjugation technology platform for development of multiple ADCs for oncology

B-Body · Invenra

Invenra's B-Body technology platform for discovery and development of novel binders and multispecific antibodies for oncology

Discontinued (4)

zanzalintinib — Squamous Cell Carcinoma of the Head and Neck · study will not proceed to phase 3 based on emerging data, competition, and assessment of other commercial opportunities
XL495 — undisclosed · discontinued further development based on early clinical data
XB064 — undisclosed · discontinued further development
XB033 — undisclosed · discontinued further development

Biotech Distilled coverage (5)

2026-06-22 UPDATE: Exelixis (EXEL) - STELLAR-303 Clears the Second Bar
2026-05-06 UPDATE: Exelixis (EXEL) - Q1 prints another cash-gusher quarter and the Board just stacked another $750M on the buyback pile. 🔒 Paid
2026-02-14 UPDATE: Exelixis (EXEL) - The Receipts Are In 🔒 Paid
2026-02-07 UPDATE: Exelixis (EXEL) - The Clock Starts Now 🔒 Paid
2026-01-30 Exelixis Inc.(EXEL): Scientific Deep Dive for Zanza and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.